Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Operating Expenses (2018 - 2025)

Serina Therapeutics' Operating Expenses history spans 8 years, with the latest figure at $6.4 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 20.02% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $23.5 million, up 105.89%, while the annual FY2024 figure was $17.1 million, 172.27% up from the prior year.
  • Operating Expenses for Q3 2025 was $6.4 million at Serina Therapeutics, up from $5.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $6.4 million in Q3 2025 and bottomed at -$165000.0 in Q4 2023.
  • The 5-year median for Operating Expenses is $2.1 million (2022), against an average of $2.8 million.
  • The largest annual shift saw Operating Expenses crashed 109.22% in 2023 before it soared 3454.55% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $1.9 million in 2021, then fell by 5.49% to $1.8 million in 2022, then plummeted by 109.22% to -$165000.0 in 2023, then skyrocketed by 3454.55% to $5.5 million in 2024, then increased by 15.48% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Operating Expenses are $6.4 million (Q3 2025), $5.7 million (Q2 2025), and $5.9 million (Q1 2025).